CHIMERIC CONSTRUCTS BETWEEN HUMAN AND RAT EQUILIBRATIVE NUCLEOSIDE TRANSPORTERS (HENT1 AND RENT1) REVEAL HENT1 STRUCTURAL DOMAINS INTERACTING WITH CORONARY VASOACTIVE DRUGS
M. Sundaram et al., CHIMERIC CONSTRUCTS BETWEEN HUMAN AND RAT EQUILIBRATIVE NUCLEOSIDE TRANSPORTERS (HENT1 AND RENT1) REVEAL HENT1 STRUCTURAL DOMAINS INTERACTING WITH CORONARY VASOACTIVE DRUGS, The Journal of biological chemistry, 273(34), 1998, pp. 21519-21525
We have recently isolated cDNAs from human placenta and rat jejunum en
coding the prototypic human and rat equilibrative nitrobenzylthioinosi
ne (NBMPR)-sensitive nucleoside transporters hENT1 and rENT1. The two
proteins (456 and 457 residues, M-r 50,000) are 78% identical in amino
acid sequence and contain 11 potential transmembrane segments (TMs) w
ith a large putative extracellular loop between TMs 1 and 2 and a larg
e cytoplasmic loop between TMs 6 and 7, When expressed in Xenopus oocy
tes, recombinant hENT1 and rENT1 transport both purine and pyrimidine
nucleosides, including adenosine, and are inhibited by nanomolar conce
ntrations of NBMPR. hENT1 is also potently inhibited by coronary vasod
ilator drugs (dipyridamole, dilazep, and draflazine), whereas rENT1 is
insensitive to inhibition by these compounds (dipyridamole IC,, value
s 190 nM (hENT1) and greater than or equal to 10 mu M (rENT1) at 10 mu
M uridine). In the present study, we have generated reciprocal chimer
as between hENT1 and rENT1, using splice sites at residues 99 (end of
TM. 2) and 231 (end of TM 6), to identify structural domains of hENT1
responsible for transport inhibition by vasoactive compounds. Transpla
nting the amino-terminal half of hENT1 into rENT1 converted rENT1 into
a dipyridamole/dilazep-sensitive transporter, whereas the amino-termi
nal half of rENT1 rendered hENT1 dipyridamole/dilazep-insensitive, Dom
ain swaps within the amino-terminal halves of hENT1 and rENT1 identifi
ed residues 100-231 (incorporating TMs 3-6) of hENT1 as the major site
of vasodilator interaction. Since these drugs function as competitive
inhibitors of nucleoside transport and NBMPR binding, TMs 3-6 are lik
ely to form part of the substrate-binding site.